COMPOUND LIBRARY AND OPTION AGREEMENTCompound License Agreement • April 23rd, 2018 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 23rd, 2018 Company Industry JurisdictionThis Compound Library and Option Agreement (the “Agreement”), dated as of February 2nd, 2016 (the “Signing Date”), is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 1700 Owens Street, Suite 535, San Francisco, California 95158. Ascentage and Unity are sometimes referred to herein as individually as a party and collectively as the parties.
FIRST AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG1197Compound License Agreement • November 25th, 2019 • Unity Biotechnology, Inc. • Pharmaceutical preparations
Contract Type FiledNovember 25th, 2019 Company IndustryThis Amendment (the “Amendment”), dated as of November 19, 2019 (the “Amendment Effective Date”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 11/F, AXA CENTRE, Gloucester Road, Wanchai, Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 3280 Bayshore Blvd, Suite 100, Brisbane, California 95002. Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”.